

Alessandro Parisi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9397800/alessandro-parisi-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

394
citations

8
h-index

19
g-index

41
ext. papers

541
ext. citations

3.6
avg, IF

3.14
L-index

#	Paper	IF	Citations
37	Concurrent RAS and RAS/BRAF V600E Variants in Colorectal Cancer: More Frequent Than Expected? A Case Report.. <i>Frontiers in Oncology</i> , 2022 , 12, 863639	5.3	0
36	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry.. <i>European Journal of Cancer</i> , 2022 , 170, 10-16	7.5	1
35	A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement?. <i>Supportive Care in Cancer</i> , 2021 , 30, 2455	3.9	1
34	Post-Induction Management in Patients With Left-Sided and Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. <i>Frontiers in Oncology</i> , 2021 , 11, 712053	5.3	3
33	How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell-Based Approaches. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	3
32	Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	4
31	What Is Known about Theragnostic Strategies in Colorectal Cancer. <i>Biomedicines</i> , 2021 , 9,	4.8	6
30	Bone recurrence in early breast cancer patients: The paradox of aromatase inhibitors induced bone resorption. <i>Breast Disease</i> , 2021 , 40, 257-262	1.6	
29	Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. <i>Cancers</i> , 2020 , 12,	6.6	10
28	The treatment paradigm of right-sided metastatic colon cancer: harboring BRAF mutation makes the difference. <i>International Journal of Colorectal Disease</i> , 2020 , 35, 1513-1527	3	4
27	Haloperidol for the treatment of opioid addiction in advanced cancer patients: a case series. <i>Journal of Addictive Diseases</i> , 2020 , 38, 229-234	1.7	2
26	Family History of Cancer as Potential Prognostic Factor in Stage III Colorectal Cancer: a Retrospective Monoinstitutional Study. <i>Journal of Gastrointestinal Cancer</i> , 2020 , 51, 1094-1101	1.6	2
25	Evaluating the role of FAMILY history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study. <i>Oncolimmunology</i> , 2020 , 9, 1710389	7.2	6
24	Expression of pro-angiogenic factors as potential biomarkers in experimental models of colon cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 1427-1440	4.9	9
23	Evaluation of Prognostic Factors for Survival in Transverse Colon Cancer. <i>Cancers</i> , 2020 , 12,	6.6	3
22	Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future. <i>Cancers</i> , 2020 , 12,	6.6	7
21	First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. <i>Clinical and Translational Oncology</i> , 2020 , 22, 158-162	3.6	7

20	The PERSONS score: A new tool for cancer patients'symptom assessment in simultaneous care and home care settings. <i>Palliative and Supportive Care</i> , 2020 , 18, 33-38	2.5	4
19	Looking for A Place for Dose-Dense TMZ Regimens in GBM Patients: An Experience with MGMT Exploratory Evaluation. <i>Bioengineering</i> , 2019 , 6,	5.3	1
18	Weekly alternate intensive regimen FIrB/FOx in metastatic colorectal cancer patients: an update from clinical practice. <i>OncoTargets and Therapy</i> , 2019 , 12, 2159-2170	4.4	6
17	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable 2019 , 7, 57		155
16	Safe Administration of anti-PD-L1 Atezolizumab in a Patient with Metastatic Urothelial Cell Carcinoma and End-Stage Renal Disease on Dialysis. <i>Case Reports in Oncological Medicine</i> , 2019 , 2019, 3452762	0.9	5
15	The PERSONS score for symptoms assessment in simultaneous care setting: A pilot study. <i>Palliative and Supportive Care</i> , 2019 , 17, 82-86	2.5	4
14	Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019 , 145, 2365-2373	4.9	6
13	Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study. <i>Journal of Cancer</i> , 2019 , 10, 5926-5934	4.5	16
12	Predictive value of skeletal muscle mass for immunotherapy with nivolumab in non-small cell lung cancer patients: A "hypothesis-generator" preliminary report. <i>Thoracic Cancer</i> , 2019 , 10, 347-351	3.2	38
11	Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice. <i>Thoracic Cancer</i> , 2018 , 9, 241-252	3.2	4
10	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. <i>Immunotherapy</i> , 2018 , 10, 643-655	3.8	9
9	Timed-flat infusion of 5-fluorouracil with docetaxel and oxaliplatin as first-line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen. <i>Oncology Reports</i> , 2018 , 40, 803-812	3.5	2
8	First-line chemotherapy with docetaxel, oxaliplatin, and timed-flat infusion 5Fluorouracil in metastatic gastro-esophageal adenocarcinomas: The experience with FD/FOx regimen.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 178-178	2.2	
7	Where are we with treatment options after first line in small cell lung cancer?-report of two opposite cases treated with CAPTEM regimen and possible perspectives. <i>Journal of Thoracic Disease</i> , 2018 , 10, E520-E525	2.6	
6	The possible different roles of denosumab in prevention and cure breast cancer bone metastases: A \hypothesis-generator\study from clinical practice. <i>Oncology Letters</i> , 2018 , 16, 7195-7203	2.6	2
5	Immune Checkpoint Inhibitors and Myasthenic Syndromes: A Case Report of a Metastatic Renal Cell Carcinoma Patient Treated With Nivolumab. <i>Journal of Clinical Neuromuscular Disease</i> , 2018 , 20, 99-100	1.1	1
4	Single-institution study of correlations between skeletal muscle mass, its density, and clinical outcomes in non-small cell lung cancer patients treated with first-line chemotherapy. <i>Thoracic Cancer</i> , 2018 , 9, 1623-1630	3.2	26
3	Safe Administration of Ipilimumab, Pembrolizumab, and Nivolumab in a Patient with Metastatic Melanoma, Psoriasis, and a Previous Guillain-Barr\syndrome. <i>Case Reports in Oncological Medicine</i> , 2018 , 2018, 2783917	0.9	2

- 2 Topical Menthol for Treatment of Chemotherapy-induced Peripheral Neuropathy. *Indian Journal of Palliative Care*, **2017**, 23, 350-352 1-3 7
- 1 High- and low-penetrance cutaneous melanoma susceptibility genes. *Expert Review of Anticancer Therapy*, **2006**, 6, 657-70 3-5 37